Cognition Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $93.4M
- Price
- $0.9819
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.74%
- Volume
- 379.8K
About
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Quick stats
Shares outstanding95.1M
Computed float79.3M
Float / shares83.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001455365
Websitehttps://www.cogrx.com
AI Summary
AI-generated1/15
standardbullishearnings
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
Cognition Therapeutics reported a Q2 net loss of $3.9 million, or $0.04 per share, narrowing from a loss of $6.7 million in the prior year period as R&D expenses dropped to $5.1 million.
The company ended the quarter with $34.8 million in cash and estimates sufficient runway to fund operations into the fourth quarter of 2027, supported by $21.6 million in remaining NIH grant funds.
Operationally, management received clarity from the FDA on the design of a planned Phase 3 trial for zervimesine in DLB psychosis and secured a patent allowance extending protection through 2045.